Tiago Girao
CIK 1618670 · Chief Financial Officer · last filed 2026-07-24
Tiago Girao is a Chief Financial Officer who has filed 23 SEC Form 4 insider transactions across 3 companies since 2014. The most recent filing shows the insider sold $263.0K of IMVT on Jul 24, 2026. Across all open-market trades the lifetime net is −$1.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
IMVT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMVT | Chief Financial Officer | 240,798 | $26.73 | $6.44M | -$1.41M | 5 | 2026-07-24 |
| Landos Biopharma, Inc. (LABP) Delisted | Director | — | $22.93 | — | $0 | 5 | 2024-05-23 |
| PLUS THERAPEUTICS, INC. (CYTX) Delisted | VP & Chief Financial Officer | 14,084 | — | — | $33.1K | 11 | 2017-11-29 |
Recent Filings
23 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-24 | IMVT | Sell (S) | −6,798 | -$263.0K | EDGAR |
| 2026-06-26 | IMVT | Notice (144) | −10,000 | -$384.6K | EDGAR |
| 2026-06-26 | IMVT | Mixed | — | -$225.6K | EDGAR |
| 2026-04-24 | IMVT | Sell (S) | −25,760 | -$763.0K | EDGAR |
| 2026-04-09 | IMVT | Grant (A) | +64,968 | $0 | EDGAR |
| 2025-05-05 | IMVT | Grant (A) | +208,388 | $0 | EDGAR |
| 2024-05-23 | Landos Biopharma, Inc. (LABP) Delisted | Disp (D) | — | $0 | EDGAR |
| 2023-05-24 | Landos Biopharma, Inc. (LABP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-09 | Landos Biopharma, Inc. (LABP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-18 | Landos Biopharma, Inc. (LABP) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.